REG - Oncimmune Hldgs PLC - Posting of Annual Report and Notice of GM

Oncimmune HoldingsAnnouncement

03/03/2023 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230303:nRSC7212Ra&default-theme=true

RNS Number : 7212R  Oncimmune Holdings PLC  03 March 2023

3 March 2023

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Posting of Annual Report and Notice of General Meeting

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, gives notice that its Annual Report and Accounts for the financial
period ended 31 August 2022 (the "Annual Report") has today been sent to
shareholders along with notice of a General Meeting ("GM"). The business of
the GM will be, amongst other things, to receive the Annual Report and to
approve the report on Directors' remuneration. The GM will be held at 10:00 am
GMT on 27 March 2023 at the offices of Pinsent Masons LLP, 30 Crown Place,
Earl Street, London, EC2A 4ES.

 

The Company's Annual Report and Accounts for the financial period ended 31
August 2022 and the Notice of GM can also be viewed on the "Investors" section
of the Company's website at www.oncimmune.com (http://www.oncimmune.com) .

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

Zeus (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

+44 (0)20 3829 5000

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSUUOVROWUORAR